Emergent BioSolutions (EBS) Consolidated Net Income (2011 - 2026)
Emergent BioSolutions (EBS) posted Consolidated Net Income of -$180.2 million for Q2 2026, down 2750.0% on a QoQ basis from $6.8 million in Q1 2026, and down 1401.67% year-over-year from $13.8 million in Q2 2025.
Powered by 
Analysis
Emergent BioSolutions (EBS) Consolidated Net Income (2011 - 2026) Analysis & Trends
Emergent BioSolutions has reported Consolidated Net Income for 16 years, with the latest figure at -$180.2 million in Q2 2026.
- On a quarterly basis, Consolidated Net Income fell 1401.67% year-over-year to -$180.2 million in Q2 2026; TTM through Jun 2026 was -$176.8 million, a 226.74% decrease from a year earlier, with the FY2025 full-year figure at $52.6 million, up 127.6% from the prior year.
- Consolidated Net Income was -$180.2 million for Q2 2026 at Emergent BioSolutions, down from $6.8 million in the prior quarter.
- The five-year high for Consolidated Net Income was $114.8 million in Q3 2024, with the low at -$283.1 million in Q2 2024.
- Average Consolidated Net Income over 5 years is -$71.4 million, with a median of -$52.0 million recorded in 2023.
- The sharpest annual moves came in 2023 and 2025: Consolidated Net Income sank 4932.43% in 2023, then surged 655.56% in 2025.
- Over 5 years, Consolidated Net Income stood at -$67.0 million in 2022, then advanced by 26.12% to -$49.5 million in 2023, then surged by 36.77% to -$31.3 million in 2024, then slumped by 74.44% to -$54.6 million in 2025, then plunged by 230.04% to -$180.2 million in 2026.
- The last three Consolidated Net Income figures came in at -$180.2 million (Q2 2026), $6.8 million (Q1 2026), and -$54.6 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 649.47 Bn | 628.71 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 467.46 Bn | 460.93 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 369.31 Bn | 362.22 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 269.03 Bn | 261.74 Bn | 11.24 Bn | 5.28 Bn |
| 5 | Pfizer | 158.11 Bn | 146.71 Bn | 10.94 Bn | -238.00 Mn |
| 6 | Bristol Myers Squibb | 127.96 Bn | 116.89 Bn | 9.25 Bn | 3.32 Bn |
| 7 | Sanofi | 51.83 Bn | 44.86 Bn | 10.79 Bn | 2.16 Bn |
| 8 | BeOne Medicines | 41.33 Bn | 36.23 Bn | 1.53 Bn | 237.01 Mn |
| 9 | Revolution Medicines | 41.30 Bn | 41.30 Bn | - | -644.37 Mn |
| 10 | Emergent BioSolutions | 335.50 Mn | 194.60 Mn | 137.20 Mn | -180.20 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -180.20 Mn |
| Mar 31, 2026 | 6.80 Mn |
| Dec 31, 2025 | -54.60 Mn |
| Sep 30, 2025 | 51.20 Mn |
| Jun 30, 2025 | -12.00 Mn |
| Mar 31, 2025 | 68.00 Mn |
| Dec 31, 2024 | -31.30 Mn |
| Sep 30, 2024 | 114.80 Mn |
| Jun 30, 2024 | -283.10 Mn |
| Mar 31, 2024 | 9.00 Mn |
| Dec 31, 2023 | -49.50 Mn |
| Sep 30, 2023 | -263.40 Mn |
| Jun 30, 2023 | -261.40 Mn |
| Mar 31, 2023 | -186.20 Mn |
| Dec 31, 2022 | -67.00 Mn |
| Sep 30, 2022 | -87.10 Mn |
| Jun 30, 2022 | -56.40 Mn |
| Mar 31, 2022 | -3.70 Mn |
| Dec 31, 2021 | 177.90 Mn |
| Sep 30, 2021 | -32.70 Mn |
API Access
Emergent BioSolutions Consolidated Net Income API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=consolidated-net-income&ticker=EBS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "consolidated-net-income", "ticker": "EBS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=consolidated-net-income&ticker=EBS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();